Regencell Bioscience Holdings Limited (RGC) — Financial statements
Income statement, balance sheet, and cash flow for Regencell Bioscience Holdings Limited — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.39↓47.3% | 0.75↓3.1% | 0.77↑27.3% | 0.60↑2184.5% | 0.03 | |
| Gross Profit | -0.39↑47.3% | -0.75↑3.1% | -0.77↓27.3% | -0.60↓2184.5% | -0.03 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.95↓11.1% | 1↓32.6% | 2↓37.0% | 3↑473.1% | 0.44 | |
| General & Administrative Expenses | 0.00↓100.0% | 3↓27.4% | 4↓12.8% | 5↑439.6% | 0.94 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.13↓52.2% | 0.26↑939.2% | 0.03↑1503.7% | 0.00 | |
| SG&A Expenses | 2↓17.0% | 3↓37.7% | 5↓8.1% | 5↑441.4% | 0.94 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 3↓15.4% | 4↓36.4% | 6↓17.6% | 8↑451.5% | 1 | |
| Total Costs & Expenses | 4↓20.4% | 5↓24.5% | 6↓17.6% | 8↑451.5% | 1 | |
| Operating Results | ||||||
| Operating Income | -4↑20.4% | -5↑24.5% | -6↑17.6% | -8↓451.5% | -1 | |
| Depreciation & Amortization | 0.39↓47.3% | 0.75↓3.1% | 0.77↑27.3% | 0.60↑2184.5% | 0.03 | |
| EBITDA | -3↑11.8% | -4↑31.6% | -5↑24.3% | -7↓415.9% | -1 | |
| EBIT | -4↑17.9% | -4↑28.0% | -6↑20.4% | -8↓451.5% | -1 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -0.19↑50.3% | -0.37↓76.7% | -0.21 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.19↓50.3% | 0.37↑76.7% | 0.21↑810.4% | 0.02↓32.9% | 0.03 | |
| Income Before Tax | -4↑17.9% | -4↑28.0% | -6↑20.2% | -8↓463.9% | -1 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -4↑17.9% | -4↑28.0% | -6↑20.2% | -8↓463.9% | -1 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -4↑16.7% | -4↑26.7% | -6↑20.9% | -7↓451.2% | -1 | |
| Bottom-Line Net Income | -4↑16.7% | -4↑26.7% | -6↑21.1% | -7↓452.9% | -1 | |
| EPS (Basic) | -0.01↑17.2% | -0.01↑26.9% | -0.01↑20.7% | -0.02↓435.7% | -0.00 | |
| EPS (Diluted) | -0.01↑17.2% | -0.01↑26.9% | -0.01↑20.7% | -0.02↓435.7% | -0.00 | |
| Weighted Average Shares | 494↑0.0% | 494↑0.0% | 494↑0.0% | 494↑2.9% | 480 | |
| Weighted Average Diluted Shares | 494↑0.0% | 494↑0.0% | 494↑0.0% | 494↑2.9% | 480 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.